CheckMyRecalls

Lupin Pharmaceuticals Inc. recalls Liraglutide Injection

Published
27 May 2026
Units affected
217,621 pen injectors
Agency
FDA
Country
United States

The hazard

Presence of particulate matter: a white thread-like structure in the cartridge

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.

Brand / company
Lupin Pharmaceuticals Inc.
Codes / lots
Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.
Distribution
Nationwide within U.S
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 27 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.